Straipsniai su viešo pasiekiamumo įpareigojimais - Alan J ThompsonSužinokite daugiau
Iš visoNIHREuropean CommissionWellcomeMultiple Sclerosis Society, UKMRCNIHEPSRCSNSFBMBFUK Research & InnovationDFGGatesDOECIHRCancer Research UKParkinson's UKGovernment of SpainNSFDoDNHMRCFWOFRQSNSERCBanking Foundation "la Caixa"Wellcome Trust/DBT India AllianceFCTSwedish Research CouncilSTFCMultiple Sclerosis Society of CanadaRoyal Society UKCanada First Research Excellence Fund
Niekur nepasiekiama: 4
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
N De Stefano, A Giorgio, M Battaglini, M Rovaris, MP Sormani, F Barkhof, ...
Neurology 74 (23), 1868-1876, 2010
Įpareigojimai: US National Institutes of Health
The self‐report Barthel Index: preliminary validation in people with Parkinson’s disease
D Morley, C Selai, A Thompson
European journal of neurology 19 (6), 927-929, 2012
Įpareigojimai: Parkinson's UK
The challenge of follow-on biologics for treatment of multiple sclerosis
SC Reingold, JP Steiner, CH Polman, JA Cohen, MS Freedman, ...
Neurology 73 (7), 552-559, 2009
Įpareigojimai: Swiss National Science Foundation, US National Institutes of Health
Longitudinal analysis framework of DWI data for reconstructing structural brain networks with application to Multiple Sclerosis
T Charalambous, F Prados, C Tur, B Kanber, S Ourselin, D Chard, ...
Computational Diffusion MRI: MICCAI Workshop, Québec, Canada, September 2017 …, 2018
Įpareigojimai: UK Engineering and Physical Sciences Research Council, UK Medical Research …
Kur nors pasiekiama: 117
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ...
The Lancet Neurology 17 (2), 162-173, 2018
Įpareigojimai: European Commission
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10269), 99-111, 2021
Įpareigojimai: Bill & Melinda Gates Foundation, US National Institutes of Health, UK …
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
M Naghavi, AA Abajobir, C Abbafati, KM Abbas, F Abd-Allah, SF Abera, ...
The lancet 390 (10100), 1151-1210, 2017
Įpareigojimai: Bill & Melinda Gates Foundation, US National Institutes of Health, Fundação …
Defining the clinical course of multiple sclerosis: the 2013 revisions
FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ...
Neurology 83 (3), 278-286, 2014
Įpareigojimai: European Commission, Multiple Sclerosis Society of Canada
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ...
The Lancet 396 (10249), 467-478, 2020
Įpareigojimai: US National Institutes of Health, UK Engineering and Physical Sciences …
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ...
The Lancet 396 (10267), 1979-1993, 2020
Įpareigojimai: Swiss National Science Foundation, US National Institutes of Health, UK …
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four …
M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ...
The Lancet 397 (10277), 881-891, 2021
Įpareigojimai: Bill & Melinda Gates Foundation, UK Medical Research Council, National …
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of …
H Wang, AA Abajobir, KH Abate, C Abbafati, KM Abbas, F Abd-Allah, ...
The Lancet 390 (10100), 1084-1150, 2017
Įpareigojimai: Bill & Melinda Gates Foundation, US National Institutes of Health, National …
MRI in multiple sclerosis: current status and future prospects
R Bakshi, AJ Thompson, MA Rocca, D Pelletier, V Dousset, F Barkhof, ...
The Lancet Neurology 7 (7), 615-625, 2008
Įpareigojimai: US National Institutes of Health
Deep gray matter volume loss drives disability worsening in multiple sclerosis
A Eshaghi, F Prados, WJ Brownlee, DR Altmann, C Tur, MJ Cardoso, ...
Annals of neurology 83 (2), 210-222, 2018
Įpareigojimai: UK Engineering and Physical Sciences Research Council, National Institute …
Progression of regional grey matter atrophy in multiple sclerosis
A Eshaghi, RV Marinescu, AL Young, NC Firth, F Prados, ...
Brain 141 (6), 1665-1677, 2018
Įpareigojimai: UK Engineering and Physical Sciences Research Council, National Institute …
Multiple sclerosis progression: time for a new mechanism-driven framework
T Kuhlmann, M Moccia, T Coetzee, JA Cohen, J Correale, J Graves, ...
The Lancet Neurology 22 (1), 78-88, 2023
Įpareigojimai: US National Institutes of Health, German Research Foundation, National …
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
D Ontaneda, AJ Thompson, RJ Fox, JA Cohen
The Lancet 389 (10076), 1357-1366, 2017
Įpareigojimai: US National Institutes of Health, National Institute for Health Research, UK
Disability, atrophy and cortical reorganization following spinal cord injury
P Freund, N Weiskopf, NS Ward, C Hutton, A Gall, O Ciccarelli, M Craggs, ...
Brain 134 (6), 1610-1622, 2011
Įpareigojimai: Swiss National Science Foundation
MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord injury: a prospective longitudinal study
P Freund, N Weiskopf, J Ashburner, K Wolf, R Sutter, DR Altmann, ...
The Lancet Neurology 12 (9), 873-881, 2013
Įpareigojimai: Swiss National Science Foundation, Wellcome Trust
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ...
The Lancet 398 (10304), 981-990, 2021
Įpareigojimai: US National Institutes of Health, UK Engineering and Physical Sciences …
Leidyklos ir finansavimo informaciją automatiškai nustato kompiuterio programa